Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

NCT05232864 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
31
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated by sponsor based on a futility analysis of the core study CAIN457Q12301

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals